Entera Bio

ENTX

Market cap $60.5M

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced the submission to the U.S. Food and Drug Administration (FDA) of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan (SAP), and open-label extension synopsis to the Company's Investigational New Drug (IND) 505(b)(2) submission, to evaluate EB613 (Oral PTH(1-34), teriparatide).

TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company's Chairman, have made open market purchases of the Company's ordinary shares. These transactions follow an earlier open market purchase by Entera Bio's Chief Executive Officer, Miranda Toledano, in December 2025.

New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026

This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities

FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613

Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below.

Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause

First-time presentation examining bone outcomes in early postmenopausal women First-time presentation examining bone outcomes in early postmenopausal women

ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.